# Evgen Pharma plc Poster presentation of SFX-01 and clinical trial update

- Link: https://www.directorstalkinterviews.com/evgen-pharma-plc-poster-presentation-of-sfx-01-and-clinical-trial-update/412762438
- Published: 2018-12-04T07:10:58+00:00
- Author: Giles Arbor

**Evgen Pharma plc** (LON: EVG), a clinical stage drug development company focused
on the treatment of cancer and neurological conditions, announced today that a trials-
in-progress poster of the Company’s Phase II trial of SFX-01 in metastatic breast
cancer will be presented this week at the San Antonio Breast Cancer Symposium 2018
in San Antonio, Texas.

The poster, entitled STEM: SFX-01 in the Treatment and Evaluation of Metastatic 
Breast Cancer, will be presented in a poster session on Wednesday 5 December 2018.
The poster gives the background to SFX-01 along with a description of the STEM trial
including its primary and second endpoints.

After a positive interim readout, recruitment in the STEM trial concluded in July
this year. The final patient on the trial will take her last dose of SFX-01 before
the end of December 2018, meaning that the final readout of the trial is expected
in February or March 2019.

The San Antonio Breast Cancer Symposium is on 4-8 December 2018 in San Antonio, 
Texas, at the Henry B. Gonzalez Convention Center. Further information is available
at this link: www.sabcs.org.

A copy of the Evgen Pharma poster will be made available on the Company’s website,
www.evgen.com, following its presentation at the San Antonio symposium.

Share on: